Fulcrum Equity Management Sells 2,484 Shares of Pfizer Inc. (NYSE:PFE)

Fulcrum Equity Management lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 14.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 14,704 shares of the biopharmaceutical company’s stock after selling 2,484 shares during the period. Fulcrum Equity Management’s holdings in Pfizer were worth $423,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Moneta Group Investment Advisors LLC lifted its position in shares of Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after acquiring an additional 160,963,976 shares in the last quarter. Norges Bank purchased a new position in shares of Pfizer in the fourth quarter valued at about $3,150,472,000. Charles Schwab Investment Management Inc. lifted its position in shares of Pfizer by 10.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after buying an additional 9,393,992 shares in the last quarter. Morgan Stanley lifted its position in shares of Pfizer by 10.3% in the fourth quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock worth $4,073,547,000 after buying an additional 7,419,929 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Pfizer in the first quarter worth about $311,238,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE:PFE traded down $0.03 during trading on Friday, reaching $27.75. 40,466,657 shares of the company’s stock traded hands, compared to its average volume of 47,662,984. Pfizer Inc. has a fifty-two week low of $25.61 and a fifty-two week high of $42.22. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The firm has a market cap of $157.14 billion, a PE ratio of 77.08, a P/E/G ratio of 1.24 and a beta of 0.61. The company has a 50-day simple moving average of $27.45 and a 200-day simple moving average of $29.45.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same period last year, the firm earned $1.14 EPS. The company’s quarterly revenue was down 41.3% on a year-over-year basis. As a group, analysts predict that Pfizer Inc. will post 2.22 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on PFE. Barclays decreased their target price on Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 14th. UBS Group decreased their target price on Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a research report on Thursday, December 14th. Guggenheim started coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research report on Thursday, January 4th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Friday, March 1st. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average target price of $36.88.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.